Bristol's High Profile TYK2 Inhibitor Disappoints In Ulcerative Colitis

Oct 07 2021

• By Jessica Merrill

Listen to this article

Deucravacitinib is an oral drug in development for a wide range of autoimmune conditions, including psoriasis and psoriatic arthritis.

Time out hands — Bristol's TYK2 inhibitor failed a Phase II study in ulcerative colitis • Source: Alamy

Bristol Myers Squibb Company has ambitious development plans for its first-in-class selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib in a wide range of autoimmune diseases, but one proof-of-concept study has come up short. The company announced on 7 October that a Phase II trial testing deucravacitinib in ulcerative colitis failed to meet the primary efficacy endpoint of clinical remission at Week 12, and missed the secondary efficacy endpoints, including clinical response, endoscopic response and histological improvement at Week 12.

The news raises some concern about the broad potential of deucravacitinib in a wide range of diseases, particularly in inflammatory...

More from Immunological

Cagrisema Leads The Charge For 2025
Mar 10 2025
• By Elizabeth Cairns
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
Mar 10 2025
• By Mandy Jackson
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
Sanofi/Regeneron’s Dupixent: A First For COPD, But Not The Last
Mar 10 2025
• By Jessica Merrill
The IL-4/13 inhibitor was approved in the US for COPD, a blockbuster-sized indication, but the commercial ramp could take time and several competitors are on its heels.
Biogen Joins Molecular Glue Degrader Club with Neomorph Pact--Test-1
Dec 10 2024
• By Saba Afreen
As it posts third-quarter numbers that again reveal the decline of revenues from its multiple sclerosis portfolio, the US biotech major is entering into the hot area of targeted protein degradation to boost its immunology and neurology pipeline.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.